A simple two-ingredient supplement, glycine combined with N-acetylcysteine (NAC), corrected a long list of age‑related abnormalities in a randomized, placebo‑controlled trial from Baylor College of Medicine. The combination, called GlyNAC, is cheap, widely available and has been studied for years by the same research group. The results, published in The Journals of Gerontology: Series A in January 2023, are striking. They also come from a very small study, which matters when deciding how much weight to give them.
The Idea Behind GlyNAC
Glutathione (GSH) is the body's main intracellular antioxidant. It helps neutralize reactive oxygen species and protects mitochondria, the cell's energy‑producing structures. The Baylor team, led by Rajagopal Sekhar, has argued that older adults develop a glutathione deficiency that drives oxidative stress, mitochondrial dysfunction, inflammation and insulin resistance.
Glutathione is built from three amino acids: glutamate, cysteine and glycine. The researchers propose that older people run short of glycine and cysteine, the latter supplied here as NAC. Taking GSH directly is not an efficient fix, so the strategy is to supply the raw materials. Earlier work in aged mice showed that GlyNAC improved GSH levels, oxidative stress, mitochondrial fatty‑acid oxidation and insulin resistance. This trial tested whether the effects carry over to humans.
How the Trial Worked
The study enrolled 24 older adults and 12 young adults. The older participants were randomized to one of two groups for 16 weeks:
- GlyNAC group (n = 12): glycine plus NAC
- Placebo group (n = 12): an isonitrogenous alanine placebo, which matches the amino acid load without supplying glycine or NAC
The young adults received GlyNAC for only two weeks. They served mainly as a benchmark for what "healthy" values look like. Measurements were taken at baseline, at 2 weeks and at 16 weeks.
The team assessed a broad panel of outcomes: GSH concentrations, oxidative stress, mitochondrial fatty‑acid oxidation, molecular regulators of energy metabolism, inflammation, endothelial function, insulin resistance and several aging hallmarks. They also measured gait speed, muscle strength, the 6‑minute walk test, body composition and blood pressure.
What the Researchers Found
At baseline, the older adults looked quite different from the young ones. They had glutathione deficiency, higher oxidative stress, impaired mitochondrial function, more inflammation, endothelial dysfunction and insulin resistance. They also showed multiple aging hallmarks, poorer physical function, larger waist circumference and higher systolic blood pressure.
According to the authors, GlyNAC, and not the placebo, improved or corrected these defects over 16 weeks. The supplement was reported as safe and well tolerated. The authors conclude that combining the benefits of glycine, NAC and GSH makes GlyNAC an effective nutritional supplement for reversing age‑associated abnormalities.
Practical Details: Dosing and Who It May Be For
The abstract does not list doses, so anyone interested should read the full paper (PMC9879756). The research group's protocol has been weight‑based, at roughly 100 mg/kg per day of each amino acid. For a 70 kg adult that works out to about 7 grams each of glycine and NAC daily. That is far above the doses in typical over‑the‑counter NAC capsules, and it is usually split into several servings across the day. Treat these figures as an approximation of the trial protocol, not as a recommendation.
The population studied was older adults, with the young group acting as a comparison. The people with the most obvious case for this approach would be older individuals with signs of metabolic and functional decline. Even so, the trial does not establish that GlyNAC helps healthy younger people, and the young adults received it for only two weeks as a reference.
NAC at high doses can cause gastrointestinal upset, and it has a distinctive sulfur odor. Anyone on medications, or with kidney, liver or other chronic conditions, should speak with a clinician before attempting a gram‑level regimen. The trial's safety data cover 16 weeks in a small group, which says little about long‑term use.
Caveats That Matter
The sample is small. Twelve people per arm is enough to detect large effects on biochemical markers. It is not enough to rule out chance findings, subgroup differences or rare side effects, and the results need replication.
Many outcomes, few participants. Testing dozens of endpoints in 24 older adults raises the risk of false positives. Several endpoints improving together is encouraging, but it is not proof.
"Reversal of aging" is a strong phrase. The measures are biomarkers and functional tests. They are not hard outcomes like fractures, hospitalizations, cardiovascular events or mortality. Corrected markers do not guarantee longer or healthier lives.
Single‑center research from the originating group. Independent replication in larger, more diverse populations would substantially increase confidence. The study was accompanied by an editorial comment in the same journal issue, which signals interest from the field but is not a substitute for replication.
Duration. Sixteen weeks shows short‑term effects. Whether benefits persist, require continued supplementation or plateau is a separate question.
The Bottom Line
The GlyNAC trial offers a biologically plausible, low‑cost approach to a real problem: age‑related glutathione depletion and its downstream effects. The signal is promising, and the placebo‑controlled design is more rigorous than much supplement research. But this is a small, early‑stage randomized trial, and the headline claim of "reversing aging hallmarks" needs larger, independent confirmation with clinically meaningful endpoints. For now, GlyNAC is best viewed as an intriguing hypothesis with encouraging data, not an established anti‑aging therapy.
